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ABSTRACT 
This study was undertaken to investigate the uptake and metabolism 
of free cobalamin (vitamin B^) by cultured human skin fibroblasts. It 
was shown that normal diploid fibroblasts in culture take up free 
cobalamin (Cbl) via a saturable, mediated process which is inhibited by 
sulfhydryl reagents and inhibitors of protein synthesis but which is 
relatively unaffected by inhibitors of glycolysis and respiration. 
Cobalamin taken up in this manner becomes associated with intracel1ular 
Cbl-dependent apoenzymes. A similar process was shown to occur in 
skin fibroblasts from patients with a deficiency of transcobalamin II 
(TC II), the plasma protein which mediates the normal process of 
Cbl uptake. It was observed that normal skin fibroblasts in culture 
synthesize TC II and secrete it into incubation medium. Synthesis 
of the transport protein does not occur in fibroblasts from TC II- 
deficient patients, indicating that the observed uptake process for 
free Cbl is not mediated by TC II. A mechanism by which an uptake 
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INTRODUCTION 
The elucidation of pathways of intermediary metabolism has often 
been closely linked to the study of clinical phenomena arising from 
circumscribed lesions, congenital or acquired, which disrupt the normal 
sequence of metabolic events. Perhaps no system better portrays this 
interplay of clinical observation and biochemical investigation than the 
study of the metabolism of cobalamin (vitamin B.^). The observation in 
1926 that liver extracts could be used to treat megaloblastic anemia (1) 
led to the further understanding of the role of vitamin and gastric 
intrinsic factor deficiency in the pathophysiology of pernicious anemia 
and culminated in the isolation of the vitamin in 1948 (2). Since that 
time, inborn errors have been observed involving almost every aspect of 
cobalamin metabolism and their study has fostered the evolving understand¬ 
ing of the normal metabolic processes involved in the molecule's ab¬ 
sorption, transport, and conversion to active coenzymes. 
This study was designed to explore further one aspect of cobalamin 
metabolism and it too has its roots in the investigation of the patho¬ 
physiology of an inborn metabolic defect. It has been observed that 
patients with a congenital deficiency of the transport protein (trans- 
cobalamin II) responsible for the cellular uptake of cobalamin, who have 
the symptoms of severe cobalamin deficiency, respond to pharmacologic 
doses of vitamin B-^, thus suggesting that cells are capable of taking up 
and utilizing free as well as protein-bound cobalamin. These observations 
prompted this in vitro investigation of the uptake and metabolism of free 
cobalamin by human fibroblasts with the goal of further illuminating 
the normal processes of cobalamin metabolism while explaining the ob¬ 
served pathologic phenomena in the clinical model. 
1 

An understanding of current concepts of cobalamin metabolism 
depends on a grasp of the salient features of the vitamin's structure 
and function. The remainder of this introduction will survey relevant 
aspects of the chemistry of the cobalamin compounds, their metabolism, 
and their function as intracellular cofactors, and includes a brief dis¬ 
cussion of the clinical features of cobalamin-related metabolic disease. 
Chemical Structure of Cobalamin 
The complex three-dimensional structure of cobalamin (vitamin Bp) 
was elucidated using x-ray crystallography in 1956 by Hodgkin et al. (3). 
The molecule (Fig. 1) consists of a planar corrin ring around a central 
cobalt atom, with a side chain extending below the plane of the ring. 
The side chain contains a 5,6-dimethylbenzimidazole ring with ribose 
and phosphate moieties, and attaches via a Co-N coordination linkage 
to the benzimidazole ring. The phosphate moiety provides a second link 
to the corrin ring. The different cobalamin compounds are character¬ 
ized by the radicals in covalent linkage to the cobalt nucleus above 
the plane of the corrin ring. Three such compounds have been found in 
mammals: hydroxocobalamin, methylcobalamin, and adenosylcobalamin. The 
commonly isolated form, cyanocobalamin, is not found in vivo and is an 
artifact of isolation. 
The central cobalt atom of the cobalamin molecule can exist in a 
monovalent, divalent, or trivalent state. Hydroxocobalamin, the naturally 
occurring form of the vitamin, has a trivalent cobalt atom; in its 
metabolism to the active coenzyme compounds, adenosylcobalamin and 
methylcobalamin, the cobalt must be reduced to a monovalent state. This 
sequential reduction from Co to Co in the formation of 
- 2 - 

FIGURE 1. Structure of the cobalamin molecule. R = CH^CONH^; R' 
CH^CH^CONH^; X = -OH,-CU,-CH3> or 51-deoxy-5'-adenosyl. 
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adenosylcobalamin has been shown in bacteria to be mediated by specific 
enzymes (4); this process, and the evidence for similar cobalamin re¬ 
ductases in mammalian cells, will be discussed in connection with the 
metabolism of adenosylcobalamin. 
Adenosylcobalamin and Methylmalonate Metabolism 
Adenosylcobalamin (AdoCbl) was the first cobalamin coenzyme to be 
described and partially purified. In 1958, Barker et al. (5) described 
a coenzyme form of "pseudovitamin B^" required for the isomerization 
of glutamate to 3-methyl aspartate in Clostridium tetanomorphum. 
Isolation yielded a substance which, on exposure to light, released 
adenine and a substance with an absorption spectrum similar to cobalamin. 
The coenzyme, adenosylcobalamin, has 51-deoxy-5'-adenosyl in the sixth 
coordination position of the cobalamin molecule. Adenosylcobalamin and 
methylcobalamin are unique in that they are the only naturally occurring 
substances known to have a direct carbon-cobalt bond. 
A role, for AdoCbl as a coenzyme in mammals--specifically, for the 
conversion of methylmalonyl CoA to succinyl CoA--was proposed in 1958 by 
Smith and Monty (6) and subsequently confirmed (7,8). Gurnani et al. (7) 
reported that mitochondrial preparations of livers from cobalamin- 
deficient rats showed normal rates of methylmalonate formation but 
markedly reduced rates of succinate production; addition of "vitamin B-^ 
cofactor" (AdoCbl) restored this activity in vitro. Stern and Friedman 
(8) reported similar results in ox liver fractions. 
Methylmalonyl CoA mutase, the enzyme for which AdoCbl is a coenzyme, 
converts methylmalonyl CoA to succinyl CoA. Methylmalonyl CoA is an 
intermediate in the pathway of propionate metabolism, as well as a 
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product of thymine metabolism. Thymine is only a minor source of 
methylmalonyl CoA; the main contribution to the intracellular production 
of methylmalonyl CoA is from propionyl CoA, an intermediate in the final 
common pathway for the catabolism of branched chain amino acids, choles¬ 
terol, and odd chain fatty acids (9) (see Fig. 2). 
The metabolism of OH-Cbl to AdoCbl was first studied in bacteria. 
Walter et al. described specific reductases responsible for the sequential 
reduction of cob[111]a1amin to cob[I]alamin in cell-free extracts of 
C. tetanomorphum (4); they reported two NADH-dependent flavoproteins 
distinguishable on the basis of their cofactor requirements and 
thermolability. Subsequently, they reported isolation and purification 
of a Cbl-specific adenosyltransferase (10). Hence, evidence favors a 
three-step metabolic pathway for the production of AdoCbl in bacteria: 
two sequential reductions of OH-Cbl followed by adenosylation of 
cob[I[alamin; each step requires a specific enzyme. 
In higher animals, AdoCbl synthesis has been shown to be a mito¬ 
chondrial process: Mahoney et al. (11) reported AdoCbl synthetic 
capability in mitochondria-enriched subcellular fractions of fibro¬ 
blasts in a system which bypassed the first reduction step; subsequently, 
Fenton and Rosenberg (12) have shown that intact, purified rat liver 
mitochondria can convert OH-Cbl to AdoCbl without bypassing any part 
of the pathway. Despite these studies, efforts to confirm an enzymatic 
pathway similar to that in bacteria have been unsuccessful to date. 
However, indirect evidence that the pathway for the synthesis of AdoCbl 
is enzymatic is provided by the observation of inborn errors of metabolism 
which result in an inability to convert OH-Cbl to AdoCbl (13). 
- 5 - 
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FIGURE 2. Role of AdoCbl in the pathways of propionate and methylmalonate 
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FIGURE 3. Conversion reaction for homocysteine to methionine for 
which MeCbl is a cofactor. 
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Methylcobalamin and Homocysteine Metabolism 
In 1956, Helleiner and Woods (14) reported the facilitation of 
methionine synthesis by adding Cbl to cell-free extracts of E. coli. 
Ten years later, Weissbach and Taylor (15) reported that methylcobalamin 
(MeCbl) is a cofactor in the remethylation of homocysteine to methionine; 
they isolated a cobamide-enzyme complex with transmethylase activity 
5 
from E. coli which, in the presence of N -methyltetrahydrofolate and S- 
adenosylmethionine, could generate methionine from homocysteine (16) 
x 14 
(see Fig. 3). Using C-labelled methyltetrahydrofolate, they demonstrated 
14 
a C-methylcobalamin-enzyme intermediate and proposed a mechanism by 
which the methyl group is transferred first from methyltetrahydro¬ 
folate to the Cbl-enzyme complex, and subsequently to homocysteine. 
The transfer of the methyl group to the Cbl-enzyme complex is facilitated 
"I" 
by the reduction of the Co to Co , which generates a strong 
nucleophile (15,16). 
The significance of this cobalamin dependent reaction is twofold: 
in addition to the metabolism of homocysteine to methionine, the methyl- 
transferase reaction serves as a source for the regeneration of demethylated 
tetrahydrofolate. Through a mechanism which is still not clearly 
established, this link to the pathway of folate metabolism plays an 
important role in the clinical manifestations of disorders of cobalamin 
metabolism (9). This will be discussed further with those disorders. 
Cobalamin Metabolism 
The synthesis of cobalamin (Cbl) is restricted to microorganisms; 
consequently, higher animals must derive Cbl from dietary sources or from 
their intestinal flora. The mammalian mechanism of transport, uptake, 
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and metabolism of Cbl is an elaborate one which carefully conserves and 
maximally utilizes the trace quantities of the vitamin present in the 
external environment. The absorption of dietary Cbl is facilitated by 
gastric intrinsic factor (IF), a glycoprotein secreted by the gastric 
mucosa which competes for the Cbl in ingested animal protein and binds 
the vitamin in the intestinal lumen (17). The successful trapping of Cbl 
by IF appears to depend on partial acid digestion of the ingested protein, 
because some achlohydric and post-partial gastrectomy patients malabsorp 
protein-bound Cbl despite normal absorption of crystalline Cbl (18). 
The IF-Cbl complex then binds to ileal receptors via a rapid, Ca++- 
dependent process which is unaffected by temperature or metabolic inhibi¬ 
tors (19,20). The receptors are specific for the IF-Cbl complex; 
binding is unaffected by the presence of large excesses of free Cbl, 
free IF, or other Cbl-binders found in plasma, saliva, granulocytes, 
and breast milk (21). However, the affinity of the complex for the 
receptor is apparently unchanged by binding of other Cbl compounds to 
IF; if a Cbl compound can effectively bind to IF, the complex can bind 
to the intestinal wall (22). 
Once bound to the ileal receptors, Cbl is absorbed by a poorly- 
understood mechanism by which the vitamin is taken into and transported 
across the intestinal epithelial cell. It is not clear whether or not 
IF is taken up with the Cbl, and little is known about the intracel1ular 
transport of the vitamin, but it is ultimately released free into the 
portal blood (23,24). This phase of absorption is slow; although the 
IF-Cbl complex associates with ileal receptors within minutes, peak 
plasma levels of Cbl are not achieved until about eight hours after 
ingestion (25). 
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The free Cbl is immediately bound by plasma globulins as it enters 
the bloodstream. Almost all newly absorbed Cbl binds to transcobalamin II 
(TC II), a 3-globulin isolated in 1963 by Hall and Finkler (26). TC II 
is synthesized by the liver and possibly by other organs (27,28) and 
represents 80-100% of unsaturated Cbl-binding capacity in human plasma 
(23). Cobalamin bound to TC II has a rapid turnover rate and most 
disappears from plasma within a few hours (29). The remainder of newly- 
absorbed Cbl binds to transcobalamin I (TC I), an a-globulin thought 
to be derived from granulocytes (30). TC I is one of the "R binder" 
proteins--a series of Cbl binders with identical amino acid sequences, 
which can be distinguished by their associated carbohydrate moieties, 
and which are secreted by a number of tissues including granulocytes, 
saliva, and breast milk (31,32). The functional significances of 
these secretory binding proteins is unclear (23). The TC I-bound Cbl 
turns over very slowly and when newly absorbed vitamin comes into 
equilibrium with total body Cbl, TC I-bound Cbl represents 75 percent 
of Cbl in plasma (33). 
When Hall and Finkler first reported the isolation of TC II in 
1963, they suggested that it might prove important in the movement of 
Cbl from the gut to other tissues (26). Since that time, the TC II- 
Cbl complex has been studied extensively both in vivo and in vitro. 
TC II has been shown to facilitate the uptake of Cbl by HeLa cells 
(34), erythrocytes (35), Ehrlich ascites tumor cells (36), L1210 
leukemia cells (37), and cultured human fibroblasts (38). 
Like the absorption of the IF-Cbl complex, TC 11-Cbl uptake has been 
shown to be a biphasic process. Parenchych and Cooper (36,39) showed 
that TC 11-Cbl uptake by Ehrlich ascites cells and by HeLa cells 
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consists of a rapid, Ca -dependent, temperature- and energy-independent 
phase followed by a slower, temperature-dependent process which can be 
inhibited metabolically. They suggested that the first component 
represents binding to a membrane receptor--a passive, physico-chemical 
reaction, and that the second component corresponds to internalization-- 
an active transport process. Youngdahl-Turner and colleagues (40) 
studied the kinetics of these two components separately in cultured human 
fibroblasts, and provided strong evidence of this interpretation. 
Studies at 4° showed saturable, Ca++-dependent binding specific for the 
TC II moiety of the complex. More than 95 percent of the Cbl bound could 
be released by trypsin, indicating that Cbl is not internalized at 4°; 
internalization occurred at 37° by a process which was pH-dependent 
and inhibited by metabolic inhibitors of endocytosis (40,41). Studies 
with double-labelled ^I-TC II-CN-[5^Co]Cbl showed that both labels 
were taken up simultaneously, suggesting that the TC 11-Cbl complex is 
taken up intact (41). 
Pletsch and Coffey (42) studied the mechanism of uptake of the 
TC 11-Cbl complex by cell fractionation studies of rat liver after 
intravenous injection of Cbl, and reported a transient association 
of Cbl with lysosomal fractions preceding its appearance in large 
quantities in the mitochondrial and soluble fractions. Further 
evidence for the association with lysosomes is provided by the obser¬ 
vation that chloroquine, an inhibitor of lysosomal activity, prevents 
the release of Cbl from TC 11-Cbl complex and consequently inhibits 
the synthesis of coenzymes (41). 
Thus, evidence has accumulated to suggest the following sequence of 
events: 1) the TC II-Cbl complex binds to specific receptors on the 
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cell surface; 2) the complex is taken up intact via adsorptive endocy- 
tosis; 3) the endocytotic vesicle fuses with a lysosome; and 4) the 
TC II-Cbl complex is degraded, allowing release of free Cbl into the cyto¬ 
sol with subsequent conversion to active coenzymes (41,42). The mechanism 
by which free Cbl is transported out of the lysosome and into mito¬ 
chondria is unknown. r 
Clinical Features of Cobalamin Related Disorders 
The clinical manifestations of Cbl-related disorders are pleomorphic. 
The clinical features of vitamin deficiency usually differ widely from 
the findings associated with inborn errors affecting intracel1ular co¬ 
enzyme activity; it is this dissociation which suggests that Cbl may 
well serve another as yet undetermined function in mammals. I will 
first discuss the cardinal manifestations of Cbl deficiency--megaloblastic 
anemia and neurologic degeneration, and the primary presenting signs 
of disorders of intracellular Cbl metabolism--methylmalonic acidemia 
(-uria), homocystinemia (-uria), and ketoacidosis; I will then describe 
the manifestations of TC II deficiency and its implications with regard 
to the metabolic consequences of this inborn error. 
Megaloblastic Anemia -- Megaloblastic changes involve all formed 
elements of blood and are usually associated with either Cbl or folate 
deficiency, though they may occur as a result of other metabolic disorders 
which impair DNA synthesis (43). Megaloblastic anemia is characterized by 
a normochromic, macrocytic anemia, leukopenia with hypersegmented poly¬ 
morphonuclear leukocytes, and thrombocytopenia. The pancytopenia is 
primarily a result of ineffective hematopoiesis (43-45); in the erythroid series, 
peripheral hemolysis also plays a role. The bone marrow is normocel1ular 
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or hypercellular and shows megaloblastic transformation of all cell 
lines. The hallmark of the megaloblastic process is "nuclear-cytoplasmic 
asynchronism" (43)—the development of cells with mature cytoplasmic 
elements and an immature nucleus. Erythrocytes are large with mature 
cytoplasm--appearing either basophilic or containing hemoglobin, 
with fine granular nuclei characteristic of early phases of erythroid 
maturation. Leukocytes and megakaryocytes are less dramatically changed 
in appearance, but also show signs of nuclear-cytoplasmic asynchronism, 
as well as increased marrow destruction (44,45). 
The pathophysiologic basis for megaloblastosis is thought to be 
impaired DNA synthesis with resultant unbalanced growth, maturation arrest, 
and cell death. The primary lesion is probably a defect in the synthesis 
of DNA precursors, notably thymidine (46), resulting in impairment of 
DNA synthesis in the absence of a block in RNA synthesis. Megaloblastic 
cells have greatly increased amounts of RNA with normal levels of DNA 
(47); DNA synthesis can be increased in vitro by the addition of 
precursors (48,49). Studies of bacterial systems with isolated impaired 
ability to make deoxyribonucleosides have shown the consequences to be 
unbalanced growth, increased cell size, increased RNA content and very 
slow DNA synthesis. This leads to slow and abnormal proliteration, 
and rapidly decreasing viability (50). The same process appears to 
occur in Cbl- or folate-deficient bone marrow. Maturation of erythrocytes 
in megaloblastic anemia is delayed, there is disruption of the normal 
cell cycle, with a prolongation of the G1 (pre-DNA synthesis) phase and 
delay of the S (DNA-synthetic) phase (48,49,51). The cells enlarge, and 
are predisposed to abnormal maturation and/or early death. This process 
can be reversed by thymidine (52), folate, or Cbl. 
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The etiology of impaired DMA synthesis in megaloblastic anemia is 
not well established. The most intriguing clue lies in the link between 
Cbl and folate. Megaloblastic anemia occurs with deficiency of either 
folate or Cbl, and pharmacologic doses of one can partially or completely 
reverse the megaloblastosis induced by deficiency of the other. This 
interrelationship implies strongly that the basis of megaloblastic trans¬ 
formation lies in a Cbl-dependent part of the folate pathway. 
5 
As mentioned earlier, N -methyltetrahydrofolate is converted to 
tetrahydrofolate during the methylation of homocysteine to form methionine 
This reaction is the basis for the "methylfolate trap" hypothesis of the 
etiology of megaloblastosis proposed by Noronha and Silverman in 1961 (53) 
They propose that Cbl deficiency limits the Droduction of demethylated 
tetrahydrofolate, "trapping" available folate compounds in methyltetra- 
hydrofolate. This limits the availability of other folate compounds 
for intracellular metabolism--notably in megaloblastic anemia, it cur¬ 
tails the supply of tetrahydrofolate needed for the conversion of dUMP 
to dTMP by thymidylate synthetase. The hypothesis is an attractive 
one: it fits with the theory of pathogenesis of megaloblastosis and 
explains the response to thymidine, folate, and Cbl in deficiencies of 
either of the latter two compounds without invoking as-yet-undiscovered 
Cbl-dependent pathways. 
Much confliciting data has been generated in efforts to confirm this 
hypothesis (43). In vitro studies of the conversion of dUMP to dTMP in 
bone marrow cells have shown the reaction to be Cbl-dependent (54); 
methyl transferase activity is reportedly decreased in the liver of 
Cbl-deficient rats (55); serum levels of N -methyltetrahydrofolate was 
elevated and clearance delayed in a group of patients with Cbl 
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deficiency (56); and isolated congenital deficiency of methyl transferase 
has been associated with megaloblastic anemia (57). All this evidence 
tends to support the proposed "folate trap" mechanism. On the other 
hand, other measurements of methyltetrahydrofolate utilization in Cbl- 
12 
deficient patients by studies of clearance and CO^ generation from 
^CH^-tetrahydrofolate have shown normal turnover of the methylated com¬ 
pound and have failed to confirm that plasma levels are elevated (58,59). 
Most difficult to explain are the data provided by children with an in¬ 
born error of Cbl metabolism resulting in failure to synthesize either 
AdoCbl or MeCbl: of the four reported cases of this disorder, only one 
child had evidence of megaloblastic anemia (60-63). Thus, though the 
role of Cbl deficiency in megaloblastic anemia is probably mediated 
by a link to the pathway of folate metabolism, the relationship is not 
straightforward, and the possibility that Cbl has a completely separate 
role in some other aspect of folate metabolism has not been ruled out. 
Neurologic Disorders -- The hallmark of the neurological disorder 
associated with Cbl deficiency is "subacute combined degeneration" of 
the spinal cord--a diffuse, uneven degeneration of myelin sheaths and 
axon cylinders beginning usually in the posterior columns of the thoracic 
cord and spreading to the lateral tracts and up and down the cord. The 
clinical syndrome has its onset in symmetric weakness and paresthesias 
of the distal extremities and progresses to ataxic and spastic paraplegia, 
the predominance of ataxia or spasticity depending on the relative 
involvement of the posterior and lateral tracts. The peripheral signs 
may be associated with a full range of cerebral manifestations, includ¬ 
ing irritability, apathy, intellectual deterioration, and psychosis (64). 
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Little is known of the pathophysiology of subacute combined degen¬ 
eration. The lack of correlation between neurologic symptoms and mega- 
loblastosis, and the observation that folate can reverse the latter but 
not the former, have led investigators to believe the Cbl-deficiency- 
induced demyelination is mediated either through the AdoCbl/methylmalonyl 
CcA pathway, or through some different mechanism not directly related to 
either known Cbl-dependent pathway. There are two major pathogenic 
mechanisms which have been proposed. One suggests that Cbl deficiency 
blocks the metabolism of methylmalonyl CoA and that accumulation of 
this compound either inhibits myelin synthesis, or leads to the incor¬ 
poration of the molecule into abnormal lipids with subsequent synthesis 
of defective myelin. The other possibility put forward is that Cbl plays 
a crucial role in the detoxification of cyanide and that subacute com¬ 
bined degeneration is a manifestation of chronic cyanide intoxication 
secondary to deficiency of the detoxifying mechanism (43). 
The first hypothesis has been supported by several in vitro 
studies of fatty acid synthesis; abnormal fatty acids have been shown 
to be made, in the setting of Cbl deficiency, by rat liver extracts 
(65), rat glial cells in culture (66), and nerve biopsy slices (67). 
Once again, however, the clinical manifestations of inborn errors of 
Cbl metabolism cast doubt on the validity of the theory. Patients 
with defects in the apoenzyme of methylmalonyl CoA mutase or with 
defects in the synthesis of AdoCbl present with severe methylmalonic 
acidemia, but are free of the stigmata of subacute combined degenera¬ 
tion (9). 
The cyanide intoxication theory has its roots in the observation 
that OH-Cbl can combine with cyanide in plasma and can even serve as 
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an antidote in cyanide poisoning (68,69). The arguments in favor of the 
failure of this clearance mechanism as the basis of neuropathology in Cbl 
deficiency rest mainly on the observations of neurologic disorders in 
cigarette smokers and notably, on observations of the syndrome of tobacco 
amblyopia, an insidious progression of visual impairment associated 
with optic atrophy (70,71). Cigarette smokers have an increased CM 
load, high levels of thiocyanate excretion, and a susceptibility to 
tobacco amblyopia with mild Cbl deficiency. These observations have 
been supplemented by other reports of neurologic disorders associated 
with populations exposed to high levels of dietary cyanide (43). 
Clinical syndromes of inborn errors of Cbl metabolism serve once again 
to show that the situation is not so simple. Although the cyanide theory 
explains why children with isolated errors of AdoCbl metabolism show 
no signs of subacute combined degeneration, it fails to explain why two 
of the four children with combined AdoCbl and MeCbl deficiency, but 
normal serum Cbl levels, did have neurologic symptoms. This argues for 
the involvement of one of the intracel1ular pathways of Cbl metabolism 
in the pathogenesis of this disorder. 
Metabolic Ketoacidosis -- Methylmalonic acid excretion is elevated 
in a large proportion of patients with Cbl deficiency (72), and has 
been considered a sensitive test which often distinguishes Cbl and 
folate deficiency (73). The methylmalonic acid excretion in these patients, 
however, is rarely severe and is not associated with obvious clinical 
manifestations. By contrast, children with inborn errors of metabolism 
leading to deficient activity of methylmalonyl Co- mutase, either due to 
defects in apoenzyme function or coenzyme synthesis, excrete massive 
quantities of methylmalonic acid and characteristically present with 
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episodes of 1ife-threatening ketoacidosis, often associated with 
hypoglycemia, hyperammonemia, and hyperglycinemia (9,74,75). 
The pathogenesis of ketoacidosis in these children is not fully 
understood. The accumulation of methylmalonic acid is easily explained 
by the block in the conversion of methylmalonyl CoA to succinyl CoA; it 
also explains why one might expect some elevation of this intermediate 
to be present in Cbl deficiency. Why this should lead to the other 
aspects of the syndrome is less obvious, and proposed mechanisms rely 
on the further role of the mutase reaction in carbohydrate metabolism. 
Accumulation of methylmalonyl CoA may reduce the availability of coenzyme 
A and consequently the supply of acetyl CoA for the TCA cycle. Methyl¬ 
malonic acid is an inhibitor of gluconeogenesis, both by direct inhi¬ 
bition of pyruvate carboxylase and by inhibition of the mitochondrial 
transport of malate, the precursor of oxaloacetate (76). In addition 
to causing hypoglycemia, this contributes to the disruption of carbo¬ 
hydrate metabolism; the combined block of the TCA cycle and gluconeo- 
genesis could lead to increased lipolysis and ketoacidosis. The 
mechanisms of hyperglycinemia and hyperammonemia are unknown (9). 
Clinical Manifestations of Transcobalamin II Deficiency 
In 1971, Hakami et al. (77) described two siblings who presented 
at three and five weeks of age with diarrhea, vomiting, and "failure 
to thrive". Both were found to have severe megaloblastic anemia in the 
face of normal serum folate and Cbl levels; both responded dramatically 
to high doses of intramuscular Cbl with complete clinical and hemato¬ 
logic recovery. The infants were found to have a complete absence of 
TC II. A similar case has been described since (78). In both cases, 
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pedigree analysis of the families and laboratory studies of their 
serum suggest a single gene defect with an autosomal recessive mode of 
inheritance. 
In the older of the two index cases, withdrawal of therapy was 
attempted at one year of age. Megaloblastic anemia recurred in six weeks, 
and the study was stopped. During this interval, biochemical determina¬ 
tions in urine and plasma revealed no increase in methylmalonic acid ex¬ 
cretion , no rise in the blood levels of homocysteine, methionine, or 
cystathione, and no change in the rate of succinate or propionate oxida¬ 
tion by peripheral leukocytes (79). Despite florid megaloblastic 
changes, the metabolic variables that reflect the Cbl-dependent pathways 
remained entirely normal. 
Given the crucial role of TC II in the cellular uptake of Cbl, one 
might expect the presentation of TC II deficiency to resemble most 
closely that of children with a combined intracellular defect of coenzyme 
synthesis, who present with methylmalonic acidemia and homocystinuria. 
In reality, the complete absence of detectable biochemical derangement 
in these children separates this syndrome both from the classical picture 
of an acquired Cbl deficiency syndrome and from the "typical" 
presentation of intracellular defects of Cbl metabolism. 
To understand where the syndrome of TC II deficiency fits into the 
spectrum of Cbl-related metabolic disease, one must analyze the 
significance of the pleomorphic nature of the manifestations of Cbl- 
related disorders.' Although most patients with acquired Cbl deficiency 
have methylmalonic acidemia, some do not (43). One might explain 
this phenomenon by suggesting that in these patients, Cbl deficiency 
causes megaloblastic anemia and neurologic disorders in susceptible 

tissues before it is severe enough to cause measurable changes in 
blood or urine levels of methylmalonic acid or homocysteine. This argu¬ 
ment would explain why acquired Cbl deficiency does not present with the 
metabolic emergencies typical of intracellular defects leading to abso¬ 
lute deficiencies of Cbl-dependent enzyme function. In this context, 
the implication of the syndrome associated with TC II deficiency is 
that here too, the intracel1ular Cbl deficiency is not absolute in all 
tissues, i.e., that some Cbl is capable of entering cells by a non-TC II- 
mediated mechanism. This suggestion is supported by the observation of 
the impressive response of these patients to high doses of Cbl and 
leads to the hypothesis that human cells possess a mechanism for the up¬ 
take and metabolism of free cobalamin. This study was undertaken to 
investigate that hypothesis. 
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MATERIALS AND METHODS 
Materials 
Eagle's Minimal Essential Medium and Earle's Balanced Salt Solu¬ 
tion were obtained from Grand Island Biological Co., Grand Island, NY. 
Fetal calf serum was purchased from Flow Laboratories, Inc., Rockville, MD. 
HEPES was obtained from Calbiochem, San Diego, CA. Chloroquine was pur¬ 
chased from Sigma Chemical Co.; N-Ethylmaleimide (NEM) was purchased 
from Eastman. Anti-human TC II antiserum was kindly provided by Dr. R.H. 
Allen, Division of Hematology, University of Colorado Medical Center. 
57 57 
Cyano[ Co]cobalamin (CN-[ Co]Cbl) was purchased from Amersham/Searle. 
Cell Culture 
Initial experiments were carried out with a representative control 
line of human diploid skin fibroblasts (line 87). This line has been 
used in previous work (40,41) to investigate the TC II-mediated uptake 
of Cbl. Comparative experiments were then performed using a diploid 
skin fibroblast line (line 181) from a patient with TC II deficiency (77). 
Cells were grown in Eagle's minimal essential medium suDplemented with 1 
percent nonessential amino acids, 10 percent fetal calf serum, and 100 
yg/ml kanamycin. There is no detectable TC II in fetal calf serum (41). 
Fetal calf serum contains approximately 300-500 pg/ml Cbl, bound to R- 
binder. Stock cultures were grown in 32 oz glass bottles which were 
gassed with 5 percent CO^/PB percent air, tightly capped, and placed in a 
37° incubator. For uptake studies, cells were seeded on 100 x 15 mm Falcon 
plastic tissue culture plates at 7.5-8.5 x 10 cell/dish and placed in a 
37° incubator with 5 percent 00^/95 percent air atmosphere. For Sephadex 
G150 column experiments, cells were grown at 37° in 150 cm plastic flasks 
which were gassed and tightly capped. Bottles were seeded at approximately 
2 x 106 cells/bottle. Cells became confluent on the third day after 
plating; experiments were performed on day 4. 
- 20 - 

Uptake of Free CN-f^ColCbl 
Uptake experiments were carried out in serum-free medium. Pre¬ 
liminary results established that uptake was comparable in the presence 
or absence of supplementary amino acids. Therefore, subsequent experi¬ 
ments were done in Earle's balanced salt solution (EBSS). With the ex- 
57 
ception of concentration studies, medium contained CN-[ Co]Cbl at a con¬ 
centration of 30 pg/ml, a molar concentration equivalent to the Cbl con¬ 
centration of medium with 10 percent serum saturated with Cbl. The growth 
medium was aspirated and the cell monolayers washed twice with 5 ml 
Dulbecco's Ca++- and Mg++-free phosphate-buffered saline (PBS). Six ml 
of incubation medium or EBSS was added. Initial experiments were carried 
out at 37° in medium with 10 mM HEPES on a revolving shaker to prevent 
contribution of an unstirred fluid monolayer. It was determined that 
shaking had no effect on uptake, and subsequent experiments were carried 
out without shaking in a humidified C0^ incubator. After incubations 
of 30 min to 8 hr, the cells v/ere washed four times with 5 ml PBS, dis¬ 
solved in 1 ml of 0.2 N NaOH, and transferred to a plastic counting 
tube. The dish was then rinsed twice using 1 ml of 0.2 N NaOH and 
rinses combined with the solubilized cells. The solubilized cells were 
counted in a Packard automatic gamma scintillation counter. An aliquot 
was assayed for cell protein by the Lowry method (80), and uptake 
expressed as pg Cbl/mg cell protein. 
Studies with metabolic inhibitors were performed by preincubation 
with inhibitor for a defined interval prior to assay of uptake of 
57 
CN-[ Co]Cbl. Uptake was then studied in incubation medium containing 
the same concentration of inhibitor. Concentrations of NaF, cyclo- 
heximide, and chloroquine were chosen to match those concentrations 
- 21 - 

which were used to evaluate the inhibitor profile of TC II-mediated 
uptake in this system (41). KCN was used in concentrations known to 
inhibit respiration (81), and NEM concentration was empirically adjusted 
to find a level that did not prove lethal to fibroblasts. In these 
experiments, total uptake (binding and internalization) was distinguished 
from internalization by harvesting with trypsin-EDTA. After incubation 
57 
of cells at 4°, trypsin-EDTA removed 95-98% of cel 1-associated Co 
radioactivity (data not shown). Hence, the term "internalization" here 
57 
applies to Co activity associated with cells which is not releasable 
57 
by trypsin, and "uptake" applies to total cel 1-associated Co activity 
associated with cells after harvesting with 0.2 N NaOH. For experi¬ 
ments with metabolic inhibitors, cells were harvested by addition of 1 
ml of trypsin-EDTA. The dishes were incubated at 37° until the cells 
were floating. The cell suspension was then transferred to a 15 ml conical 
centrifuge tube and the dish washed with ice-cold growth medium. The 
suspension was centrifuged at 1800 g for 3 min at 4°C. The supernatant 
was removed to a plastic counting tube and counted. The cell pellet 
was dissolved in 0.2 N NaOH, counted, and cell protein determined. 
Intracellular Metabolism of Free Cbl 
57 
To determine the fate of CN-[ Co]Cbl taken up by monolayers, cell 
extracts were prepared and analyzed by Sephadex G150 profiles. The cells 
were harvested with trypsin and the cell pellet was sonicated for 3x15 
sec intervals. The extract was centrifuged at 18,000 g for 10 min, then 
the supernatant was loaded onto a Sephadex G150 (Pharmacia) column and 
eluted with buffer containing 0.15 M NaCl and 50 mM potassium phosphate, 
57 
pH 7.4. 1 .85 ml fractions were collected and counted for Co radioactivity. 
For column profiles in the presence of chloroquine, the 6 hr uptake 
was preceded by a one hr preincubation with chloroquine. 
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RESULTS 
Kinetics of Free CN-[^Co]Cbl Uptake 
57 
For a preliminary estimate of the magnitude of free CN-[ Co]Cbl 
57 
uptake, an experiment was performed comparing uptake of CN-[ Co]Cbl 
at 30 pg/ml in serum-free medium to that in medium containing 10 percent 
human serum. After a two hour incubation, cells in serum-free medium took 
up 1.43 pg/mg protein, as compared with an uptake of 6.41 pg/mg protein 
by monolayers in 10 percent human serum. The latter value is comparable 
to results of previous experiments with fibroblasts (82). 
Fig. 4 shows the time course of uptake in serum-free medium from 
ten min to eight hrs. Uptake is a biphasic process: the first component 
is rapid, nonlinear, and complete within less than 30 min; the second 
phase is linear and does not plateau within eight hrs. 
Saturabilit.y of Uptake 
57 
The uptake of free CN-[ Co]Cbl as a function of concentration is 
shown in Fig. 5a. To identify non-specific uptake, parallel plates 
were incubated at each concentration up to 90 pg/ml in the presence 
of a large excess of unlabelled CN-Cbl. By comparing uptake in the 
presence and absence of an excess of unlabelled Cbl, the concentra¬ 
tion curve can be resolved into two components (Fig. 5b). Uptake in 
the presence of unlabelled CN-Cbl is linearly proportional to concen¬ 
tration and nonsaturable; this uptake is defined as non-specific. 
Subtraction of non-specific uptake from total uptake allows derivation 
of a curve representing an uptake process which is nonlinear and 
saturable. 

















FIGURE 4. Time course of uptake of free Cbl. Cells were incubated at 
37° in serum-free medium with 30 pg/ml CN-[57Co]Cbl and 
solubilized in 0.2 N NaOH. This curve and others to follow 
show results of a representative experiment; each point is 
the average of duplicate determinations. 
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FIGURE 5. Uptake of CN-[ Co]Cbl as a function of concentration. Cells 
incubated at 37° for two hours. Fig. 5b reproduces part of 
curve 5a indicated in box. At these concentrations, parallel 
plates were incubated in the presence of an excess of unlabelled 
CN-Cbl. Dotted line shows derived saturable component of uptake. 
See text for details. Closed circles = total uptake. Open 
circles = nonspecific uptake in the presence of excess unlabelled 
CN-Cbl. 






Uptake of OH-Cbl 
To determine whether OH-Cbl was equally active in this system, 
an experiment was performed comparing the effectiveness of unlabelled 
OH-Cbl and unlabelled CN-Cbl in preventing the uptake of CN-[57Co]Cbl. 
Fig. 6 reveals that CN-Cbl and OH-Cbl are equally effective in com- 
57 
peting for uptake. Subsequent studies of the uptake of 0H-[ Co]Cbl 
as a function of concentration showed uptake comparable to the uptake 
of CN-[57Co]Cbl (Fig. 7). 
Effect of Metabolic Inhibitors on CN-T^ColCbl Internalization 
Experiments were performed with metabolic inhibitors to determine 
the metabolic requirements of the internalization of Cbl. Results are 
summarized in Table 1. Cycloheximide (50 pM), a protein synthesis 
inhibitor which has been shown previously to inhibit internalization 
of the TC 11-Cbl complex (41), inhibits CN-[^7Co]Cbl internalization 
by 80 percent. NaF (100 pM), a inhibitor of glycolysis, which inhibits 
TC 11-Cbl internalization by 50 percent (41), has no effect on the in¬ 
ternalization of free Cbl. KCN in concentrations sufficient to inhibit 
respiration (10 mM) inhibits free Cbl internalization by only 10 percen 
N-ethylmaleimide, which binds sulfhydryl groups, is lethal to cells at 
100 pM; at 10 pM, it inhibits internalization of CN-[^7Co]Cbl by 76 
percent. Chloroquine (5n pM), an inhibitor of lysosomal hydrolase 
activity, inhibits internalization 25 percent after a 1 hr preincuba¬ 
tion and 4G percent after a 2 hr preincubation. Further studies of 
the effects of chloroquine are presented below. 
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FIGURE 6. Competition for CN-[" Co]Cbl uptake by excess of unlabelled 
CN-Cbl and OH-Cbl. Cells incubated at 37° for two hours 
with 30 pg/'ml CN-[5?Co]Cbl. Results expressed as percent of 
control uptake in the absence of unlabelled Cbl. 
















Inhibitor % Inhibition of Internalization 
Normal Cells TC II-deficient Cells 
Cycloheximide (50 pM) 80% 44% 
NaF (100 pM) 0% 0% 
KCN (10 mM) 10% 31% 
NEM (10 mM) 76% 41% 
Chloroquine (50 yM) 25-40% 0-10% 
Table 1: Inhibitor profile for normal and TC II-deficient cells. Cells 
preincubated in inhibitor for 1 or 2 hrs prior to uptake. In¬ 
cubation medium for uptake contained 30 pg/ml CN-[57Co]Cbl and 
inhibitor. After 2 hr uptake, cells were harvested with trypsin 
EDTA and inhibition expressed as % inhibition of internalization 
Each value is an average of duplicate determinations. A repre¬ 
sentative experiment is shown. 
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Intracel 1 ular Metabolism of CN-f^ColCbl 
To confirm that free Cbl taken into cells is metabolized to active 
57 
coenzymes, a cell extract of monolayers incubated in 30 pg/ml CN-[ Co]Cbl 
for six hours was loaded on a Sephadex G150 column. The elution profile 
57 
is shown in Fig. 8. There are three peaks of Co activity: the first 
corresponds to the Cbl-dependent apoenzyme (85), the third represents 
free Cbl. The second peak co-chromatographs with TC II. To confirm 
that this peak is, in fact, TC II, a second cell extract was prepared 
after a six hour incubation. Prior to loading onto Sephadex G150 columns, 
half was incubated for one hour at 4° with control rabbit serum and the 
other half with purified rabbit anti-TC II antiserum. The two sera were 
preincubated with unlabelled CN-Cbl before addition to the sonicate, to 
saturate endogenous TC II which was found to exist in rabbit serum (data 
not shown). The results of the two Sephadex G150 profiles are shown in 
Fig. 9. The three peaks noted above are seen again in the profile of 
the sonicate incubated with control serum; in the sonicate exposed to 
anti-TC II antiserum, the second peak moves to the void volume, confirm¬ 
ing that this peak is, in fact, TC II. Hence, it appears that fibroblasts 
make TC II. To determine whether the cells also secrete TC II into the 
medium, an elution profile of post-incubation medium was obtained. As 
57 
expected, over 90 percent of Co activity was associated with free Cbl; 
however, there was a measurable peak of TC II-associated radioactivity 
57 
representing four percent of total Co activity. 
Studies with TC II-Deficient Fibroblasts 
The unexpected discovery that normal fibroblasts make TC II 
suggested that the saturable component of uptake might, in fact, 





FIGURE 8. Sephadex G150 elution profile of normal fibroblast extract 
after six hour uptake of CN-[57c0]Cbl. See text for details. 
Arrow indicates void volume. Recovery was 100 percent. 
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FIGURE 9. Sephadex G150 elution profile for six hour uptake of 
CN-[57co]Cbl by normal fibroblasts. Upper figure shows 
profile of cell extract incubated for one hour at 4° with 
control rabbit serum; lower figure shows profile of ex¬ 
tract incubated at 4° with anti-TC II antiserum. For 
details, see text. Recovery was 100 percent. 
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were repeated with fibroblasts derived from TC II-deficient patients. 
The uptake of free Cbl by control and TC II-deficient fibroblasts as a 
function of time and concentration is shown in Fig. 10 and 11. Though 
at 30 pg/ml the uptake over time is greater for the control cells than 
the TC II-deficient cells, this difference is not seen at higher concen¬ 
trations. Once again, the curves for the TC II-deficient cells are bi- 
phasic, suggestive of a nonlinear, saturable component of uptake. 
A Sephadex G150 elution profile was obtained for the TC II defi¬ 
cient cells. Because the uptake at six hours at 30 pg/ml was so much 
lower for this cell line, difficulty was encountered in obtaining uptake 
of sufficient counts to run a column. Consequently, the profile was 
done after a six hour incubation in 90 pg/ml CN-[ Co]Cbl, A profile 
was also obtained at 90 pg/ml in control cells. The two elution patterns 
are compared in Fig. 12. Two characteristics of the TC II deficient 
cell are remarkable. First, the profile of the mutant cells has no 
peak corresponding to TC II, thus confirming that these cells are 
truly deficient in the transport protein. Second, the cells also con¬ 
tain a reduced proportion of free Cbl-associated radioactivity. 
Almost all of the radioactivity is associated with the single peak 
corresponding to the Cbl-dependent apoenzymes. 
Inhibitor Profile 
The inhibitor profile for TC II-deficient cells is compared to that 
57 
of normal cells in Table 1. Cycloheximide and NEM inhibit CN-[ Co]Cbl 
internalization significantly, though less than in normal cells. As in 
controls, NaF does not inhibit internalization of the free vitamin. KCN 
inhibits internalization of Cbl by 31%, considerably more than in control 
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FIGURE 10. Comparison of CN-[57Co]Cbl uptake by control and TC II- 
deficient fibroblasts as a function of time. Closed 
circles = Control, line 87. Open circles = TC II-deficient 
cells, line 181. 











FIGURE 11. Comparison of CN-[^Co]Cbl uptake by control and TC II- 
deficient fibroblasts as a function of concentration. 
Closed circles = control, line 87. Open circles = TC II 
deficient cells, line 181. 
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FIGURE 12. Comparison of Sephadex G150 profile of cell extracts of 
control (87) and TC II-deficient (181) fibroblasts after 6 hr 
incubation in 90 pg/ml CN-[57Co]Cbl. Free Cbl-associated 
57Co activity represents 25 percent of non-TC II associated 
activity in control cells, as compared with 10 percent of 
57Co activity in mutant cells. Arrow indicates void volume. 
Recovery was 100 percent. 




cells. This was noted to be associated with a 15 percent decrease in 
cell protein in those dishes, and may indicate that for some reason, 
KCN is especially toxic to these cells. 
Effect of Chloroquine on Uptake of Free Cbl 
To investigate the role of lysosomes in the uptake process and 
to further analyze the inhibition of free Cbl uptake by chloroquine a 
Sephadex G150 profile was obtained of a cell extract of fibroblasts 
(line 87) which had been preincubated for one hour in chloroquine and 
57 
then incubated for six hours in uptake medium with 90 pg/ml CN-[ Co]Cbl 
and 50 pM chloroquine. The profile is shown in Fig. 13. Uptake in 
the presence of chloroquine leads to peaks of free Cbl and apoenzyme- 
57 
associated Co activity which are much reduced over control conditions 
(compare to Fig. 12). The TC II-associated activity is greatly increased. 
Internalization of Cbl by TC II-deficient cells in the presence 
of chloroquine (Fig 14) is essentially unchanged. There is still a 
single major peak of radioactivity associated with apoenzymes and 
little free CN-[^7Co]Cbl. 
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FIGURES 13 and 14. Sephadex G150 uptake profile of cell extract of 
control cells (line 87) and TC II-deficient cells 
(line 181) in presence of chloroquine. Cells were 
preincubated for one hour in 50 pM chloroquine, 
followed by a 6hr incubation in 90 pg/mi CM-[”Co]Cbl 
and 50 pM chloroquine. See text for details. 
Free Cbl peak represents 13 percent of 57g0 activity 
in mutant cells, and 10 percent of ^Co activity in 
control cells. TC II-associated activity in control 
cells is increased from 27 percent under control 
conditions (Fig. 12) to 45 percent of 57g0 activity; 
apoenzyme-associated activity is decreased from 36 
percent to 22 percent. 
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DISCUSSION 
The experiments described above lead to two major conclusions: 
1) that normal human diploid fibroblasts in tissue culture synthesize 
TC II and secrete it into culture medium, a property not observed in 
cultured mutant fibroblasts derived from patients with serum deficiency 
of that protein, and 2) that normal and TC II-deficient cells share a 
mechanism for the uptake of free Cbl which is independent of TC II. 
Evidence for the synthesis and secretion of TC II by fibroblasts 
in culture lies in the observation of a CN-[ CojCbl binding capacity 
which co-chromatographs with TC II on Sephadex G150, which reacts with 
purified anti-human TC II antiserum, and which accumulates in incubation 
medium over time. The observation that TC II-synthetic capability is 
expressed by fibroblasts in culture allows the further characterization 
of the defect which is expressed as complete absence of TC II in serum. 
Fibroblasts cultured from TC II-deficient patients lack Cbl-binding 
capacity in the TC II region of the Sephadex G150 profile; this sug¬ 
gests that these cells either do not synthesize TC II or that they 
synthesize an abnormal protein which is unable to bind Cbl. 
Although the synthesis of TC II by human cells in culture has not 
been described previously, synthesis of the transport protein has been 
reported in cultured rat parenchymal cells (84) and mouse fibroblasts 
(85). The j_n vivo significance of the i_n vitro synthesis of a serum 
transport protein by cell lines serially propagated in culture is 
difficult to evaluate. The production of TC II has also been observed 
in isolated, perfused dog heart, spleen, kidney, and liver (86). The 
latter two organs have been considered sites of synthesis and secretion 
of TC II (28), but the heart and spleen would be unusual secretory sources 
- 46 - 

of plasma transport proteins; their production of TC II argues for wide¬ 
spread endogenous synthesis of TC II in mammalian tissues. 
If these observations in vitro are considered to reflect wide¬ 
spread synthesis of TC II in vivo, one might then speculate as to the 
functional significance of that synthesis. Hall and Rappazzo (28) have 
reported that the capacity for uptake of free Cbl is enhanced in those 
organs which produce TC II. However, one cannot suggest that 
endogenous TC II functions to facilitate uptake of free Cbl, since, with 
the possible exception of the liver, peripheral tissues are exposed only 
to Cbl which is already bound to transport proteins. Alternatively, 
peripheral production of TC II may be an evolutionary vestige with no 
physiologic significance, although the possibility that TC II plays an 
as-yet-unknown intracellular function has not been excluded. 
These experiments have also identified a TC II-independent uptake 
process for Cbl'common to both control and TC II-deficient cells. This pro¬ 
cess is biphasic, with a saturable, specific component which is 
saturated at physiologic concentration and which reaches asteady state within 
thirty minutes. Uptake is inhibited by inhibitors of protein synthe¬ 
sis and by disulfide bond reductants; it is relatively unaffected by 
inhibitors of glycolysis and respiration. These characteristics sug¬ 
gest a specific, receptor-mediated process which is energy-independent; 
it is most consistent with a process of facilitated diffusion. 
A free Cbl-specific receptor has been described in bacterial 
systems (87,88); Fiedler-Nagy et al. have also reported specific bind¬ 
ing of free Cbl to preparations of rat liver membranes (89). The 
latter is the only other evidence to date of a specific uptake mechanism 
for free Cbl in higher animals. The results reported in rat liver 
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membranes are remarkable for the observation of binding of free Cbl of 
a magnitude similar to that mediated by TC II. The Fiedler-Nagy experi¬ 
ments measured binding, rather than total uptake. However, if the first 
component of uptake is considered to represent binding, as was proposed 
in early studies of TC II-Cbl uptake (36,37), the observation by Fiedler- 
Nagy of approximately equal binding of free Cbl and TC 11-Cbl differs 
from previous observations of facilitation of Cbl uptake (binding and 
internalization) by TC II (34,35), as well as from the results obtained 
in the present study. The reason for this discrepancy is unclear, 
although the possibility exists that this unusual avidity for free 
Cbl is a property unique to liver parenchyma. Such an avidity might 
explain the clinical manifestations of TC II deficiency and provide 
insight into the physiologic significance of the saturable uptake 
process for free Cbl. The uptake of free Cbl when present in physiologic 
concentrations is inadequate in stem cells of rapidly proliferating 
tissue to prevent megaloblastic transformation, mucosal ulcerations, 
and intestinal malabsorption. However, one may infer that it is adequate 
in liver parenchyma to prevent methylmalonic acidemia and homocystinuria, 
since these abnormalities do not develop. Whether this suggests that 
the liver's demand for Cbl is less, or its avidity for the vitamin 
more than that of stem cells, is unclear. 
At the pharmacologic doses which successfully treat TC II deficiency, 
which leads to serum Cbl concentrations of 2000-5000 pg/ml, uptake is 
primarily nonspecific. Whether uptake of free Cbl at these concentrations 
occurs by simple diffusion, bulk phase pinocytosis, or some other non¬ 
specific process remains unclear. 
Comparison of the Sephadex G150 profiles of normal and TC II 
57 
deficient cells exposed to CN-[ Co]Cbl provides further insight into 
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the mechanism of uptake of free Cbl. The absence of significant free 
Cbl-associated radioactivity in TC II-deficient cells suggests that the 
presence of intracel lular free Cbl is a characteriStic only of TC II- 
mediated uptake. These observations could be explained by the role of 
lysosomes in the metabolism of the TC 11-Cbl complex as follows: as 
discussed in the introduction, the TC II-Cbl complex is thought to be 
taken up intact by adsorptive endocytosis and digested within lysosomes 
this results in the release of free Cbl and its subsequent transport 
out of the lysosome into the cytoplasm where it can be metabolized to 
its active forms. Thus, it seems possible that the free Cbl-associated 
57 
Co activity in normal fibroblasts may represent Cbl still residing 
within lysosomes where it is unavailable for immediate conversion to 
57 
coenzymes. It then follows that the association of all Co activity 
in mutant cells with Cbl-dependent enzymes implies that the internali¬ 
zation of Cbl by these cells is followed by synthesis of coenzymes and 
association with apoenzymes with sufficient rapidity to prevent 
accumulation of free Cbl; i.e., that free Cbl is not taken up into 
lysosomes, but enters the cytoplasm directly. This hypothesis is 
supported by the observation that chloroquine, which leads to the 
accumulation of TC 11-Cbl within lysosomes (41), abolishes most of the 
free Cbl-associated radioactivity in normal cells. Thus it appears 
that the uptake of free Cbl by fibroblasts cccurs by receptor-mediated 
facilitated diffusion which leads to direct entry of the vitamin to 
the cytoplasm. 
If this uptake process is considered to occur in vivo, one might 
again speculate as to the physiologic significance of the observations 
which have been made. Since the TC II-mediated uptake process is more 
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efficient and is certainly the crucial means of uptake in those cells 
which have large Cbl requirements, it is not obvious what evolutionary 
pressures might exist for maintenance of a mechanism for the uptake of 
free Cbl. There is nothing to exclude the possibility that the mechanism 
observed in these experiments is merely a remnant of an evolutionary 
period preceding the development of more efficient uptake processes. 
However, there is a place for transport systems for free Cbl in mammalian 
tissues. Though the plasma transport and cellular uptake of Cbl is 
mediated by TC II, intracellular metabolism of the TC II-Cbl complex 
requires the movement of Cbl out of lysosomes and into mitochondria. 
This suggests a scheme whereby the free Cbl uptake system described 
here might have a role in normal Cbl metabolism. In the course of endo- 
cytosis of the TC 11-Cbl complex, a portion of the plasma membrane 
becomes first incorporated into a phagosome, and subsequently becomes 
part of the lysosomal membrane. In this process the plasma membrane 
becomes everted. If that membrane fragment contained a receptor for 
free Cbl capable of mediating facilitated diffusion of Cbl into the 
cell, it might then neatly fulfill a function as a mediator of free 
Cbl passage out of the lysosome (Fig. 15). Certainly this proposed 
mechanism at present 1 -jes in the realm of pure speculation; it does, 
however, describe a cellular economy which is more appealing than the 
relegation of the uptake process to the category of evolutionary 
castoffs which have lost their function. 
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FIGURE 15. Proposed mechanism of role of free-Cbl uptake process 
in intracellular Cbl metabolism. See text for details. 
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